Biliary tract cancers: Finding better ways to lump and split

Journal of Clinical Oncology

Volumn 33, Issue 24, 2015, Pages 2588-2590

  Kelley, Robin K ^a   Bardeesy, Nabeel ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CAPECITABINE; GEMCITABINE; K RAS PROTEIN; ANTINEOPLASTIC AGENT;

BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CHOLESTASIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; EDITORIAL; GALLBLADDER CARCINOMA; GENETIC HETEROGENEITY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; GALLBLADDER NEOPLASMS; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE;

EID: 84940473506     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.6953     Document Type: Editorial

References (28)

1. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al: SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 33:2617-2622, 2015
2. Horgan AM, Amir E, Walter T, et al: Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis. J Clin Oncol 30:1934-1940, 2012
3. Neoptolemos JP, Moore MJ, Cox TF, et al: Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. JAMA 308:147-156, 2012
4. Takada T, Amano H, Yasuda H, et al: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685-1695, 2002
5. Benson AB 3rd, D'Angelica MI, Abrams TA, et al: Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw 12:1152-1182, 2014
6. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-1281, 2010
7. Jarnagin WR, Ruo L, Little SA, et al: Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: Implications for adjuvant therapeutic strategies. Cancer 98:1689-1700, 2003
8. Hong JC, Petrowsky H, Kaldas FM, et al: Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J Am Coll Surg 212:514-520; discussion 520-521, 2011
9. Andersen JB, Spee B, Blechacz BR, et al: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142:1021-1031; e15, 2012
10. Graham RP, Barr Fritcher EG, Pestova E, et al: Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol 45:1630-1638, 2014
11. Borger DR, Tanabe KK, Fan KC, et al: Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17:72-79, 2012
12. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010
13. Rizvi S, Gores GJ: Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145:1215-1229, 2013
14. Brieau B, Dahan L, De Rycke Y, et al: Second-line chemotherapy for advanced biliary tract cancer after failure of gemcitabine plus platinum: Results of an AGEO multicenter retrospective study. J Clin Oncol 32:278s, 2014 (suppl; abstr 4093)
15. Simbolo M, Fassan M, Ruzzenente A, et al: Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 5:2839-2852, 2014
16. Jiao Y, Pawlik TM, Anders RA, et al: Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45:1470-1473, 2013
17. Arai Y, Totoki Y, Hosoda F, et al: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59:1427-1434, 2014
18. Li M, Zhang Z, Li X, et al: Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 46:872-876, 2014
19. Churi CR, Shroff R, Wang Y, et al: Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS One 9:e115383, 2014
20. Kim HS, Mendiratta S, Kim J, et al: Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155:552-566, 2013
21. Hoadley KA, Yau C, Wolf DM, et al: Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158:929-944, 2014
22. Choi W, Porten S, Kim S, et al: Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152-165, 2014
23. Damrauer JS, Hoadley KA, Chism DD, et al: Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111:3110-3115, 2014
24. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244-250, 2015
25. Waddell N, Pajic M, Patch AM, et al: Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495-501, 2015
26. Morgan MA, Shilatifard A: Chromatin signatures of cancer. Genes Dev 29:238-249, 2015
27. Bitler BG, Aird KM, Garipov A, et al: Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21:231-238, 2015
28. Rooney MS, Shukla SA, Wu CJ, et al: Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160:48-61, 2015